tbuckley/cabot-search huggingface dataset:
Lingering Questions Concerning Intensive Care Unit Utilization—Reply
Authors: Dong W. Chang, Martin F. Shapiro
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2
Authors: Jakub Tolar, Julie Curtsinger, Ron McElmurry, Valarie McCullar, Michael R. Verneris, Frits van Rhee, Natalia Lapteva, Cliona M Rooney, John E. Wagner, Bruce R. Blazar, Jeffrey S. Miller
Journal: Blood (2012)
The Relationship of Obesity to Hospice Use and Expenditures
Authors: John A. Harris, Elena Byhoff, Chithra R. Perumalswami, Kenneth M. Langa, Alexi A. Wright, Jennifer J. Griggs
Journal: Annals of Internal Medicine (2017)

Obesity complicates medical, nursing, and informal care in severe illness, but its effect on hospice use and Medicare expenditures is unknown.To describe the associations between body mass index (BMI) and hospice use and Medicare expenditures in the last 6 months of life.Retrospective cohort.The HRS (Health and Retirement Study).5677 community-dwelling Medicare fee-for-service beneficiaries who died between 1998 and 2012.Hospice enrollment, days enrolled in hospice, in-home death, and total Medicare expenditures in the 6 months before death. Body mass index was modeled as a continuous variable with a quadratic functional form.For decedents with BMI of 20 kg/m2, the predicted probability of hospice enrollment was 38.3% (95% CI, 36.5% to 40.2%), hospice duration was 42.8 days (CI, 42.3 to 43.2 days), probability of in-home death was 61.3% (CI, 59.4% to 63.2%), and total Medicare expenditures were $42 803 (CI, $41 085 to $44 521). When BMI increased to 30 kg/m2, the predicted probability of hospice enrollment decreased by 6.7 percentage points (CI, -9.3 to -4.0 percentage points), hospice duration decreased by 3.8 days (CI, -4.4 to -3.1 days), probability of in-home death decreased by 3.2 percentage points (CI, -6.0 to -0.4 percentage points), and total Medicare expenditures increased by $3471 (CI, $955 to $5988). For morbidly obese decedents (BMI ≥40 kg/m2), the predicted probability of hospice enrollment decreased by 15.2 percentage points (CI, -19.6 to -10.9 percentage points), hospice duration decreased by 4.3 days (CI, -5.7 to -2.9 days), and in-home death decreased by 6.3 percentage points (CI, -11.2 to -1.5 percentage points) versus decedents with BMI of 20 kg/m2.Baseline data were self-reported, and the interval between reported BMI and time of death varied.Among community-dwelling decedents in the HRS, increasing obesity was associated with reduced hospice use and in-home death and higher Medicare expenditures in the last 6 months of life.Robert Wood Johnson Foundation Clinical Scholars Program.
A 12-week regimen with interdigitating FOLFOX/bevacizumab and pelvic chemoradiation for synchronous primary and metastatic rectal cancer. The CHROME B trial
Authors: S. Ngan, M. Bressel, J. Chu, J. McKendrick, S. Chander, P. Cooray, M. Jefford, R. Wong, M. Steel, T. Leong, A. Heriot, M. Michael
Journal: Annals of Oncology (2016)
Using Chinese herbal medicine among cancer survivors: Data from a community hospital in China.
Authors: Ying Wang, Hui Wang, Yu Wan, Xiaoyan Wang, Yiling Jiang, Han Zhang, Yuhua Zhao, Feng Chai, Hongming Fang, Weidong Lu
Journal: Journal of Clinical Oncology (2016)

e284 Background: Chinese Herbal Medicine (CHM) is a major component of Traditional Chinese Medicine (TCM) that is widely used in Asian countries. In China, an estimated 397.7 million outpatients and 14.8 million inpatients were cared by TCM physicians and hospitals annually. TCM usage is even higher among pts with cancer. It is reported that 80% of pts with cancer use CHM and 90% of oncologists have prescribed CHM in practice. We reviewed CHM practice among cancer survivors in our hospital, a community general hospital with 800 beds located in the east coast of China. Methods: A retrospective review was conducted by searching outpatient medical records from June 2012 to August 2015. Pts were eligible if pts have pathologically proven cancer and who have completed main anticancer therapies and used CHM prescribed in the outpatient clinic. Descriptive statistical and survival analysis were performed using SPSS. Results: A total of 300 pts were identified, with a median age of 62 years (31-90), 53% were male, with 36 types of cancers. The most common cancers were lung (32%), breast (15%), colorectal (12%), stomach (9%) and liver (6%). 48% pts had stage IV disease. 47% pts used CHM for health maintenance and 53% pts used CHM for anticancer intent. 57% pts used CHM exclusively and 43% used CHM in addition to standard therapies. The median number of outpatient visits was 17 (1-158) with an average of 19 prescribed herbs per person at each visit. During the period, 36% pts passed away with a median overall survival of 24. 9 months (2-108 months). Conclusions: Using CHM for health maintenance or anticancer intent is common among Chinese cancer survivors. A majority of cancer survivors used CHM exclusively without other interventions. Future research should focus on whether using CHM has any survival benefits in cancer survivors.
Deferasirox Safety Profile in Patients with Transfusion-Dependent Anaemias:Results From the Interim Analysis of a Hellenic Study,
Authors: Vassilis Ladis, Marouso Drossou, Dimitria Vini, Ersi Voskaridou, Miranda Athanasiou-Metaxa, Marina Oikonomou, Efthimia Vlachaki, Anna Tigka, Christos Tzavelas, Theodora Liakopoulou, Eleni Vrettou, Ioannis Adamopoulos, Antonis Kattamis
Journal: Blood (2011)
Natural History of Conversion of Leber's Hereditary Optic Neuropathy
Authors: Tiffany Jean Hwang, Rustum Karanjia, Milton Nunes Moraes-Filho, Jesse Gale, Jeffrey Show Tran, Edward R. Chu, Solange R. Salomao, Adriana Berezovsky, Rubens Belfort, Milton Nunes Moraes, Federico Sadun, Anna Maria DeNegri, Chiara La Morgia, Piero Barboni, Carolina do V.F. Ramos, Carlos Filipe Chicani, Peter A. Quiros, Valerio Carelli, Alfredo A. Sadun
Journal: Ophthalmology (2017)
Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.
Authors: Eileen Scigliano, Celia Grosskreutz, Steven Fruchtman, Janice Gabrilove, John Mandeli, Luis Isola
Journal: Blood (2005)
Phase I/II pharmacokinetics/pharmacodynamics study of irinotecan and S-1 for recurrent/metastatic breast cancer in patients with select UGT1A1 genotypes (the JBCRG-M01 study)
Authors: S. Saji, H. Ishiguro, S. Nomura, H. Iwata, S. Tanaka, T. Ueno, M. Onoue, T. Yamanaka, Y. Sasaki, M. Toi
Journal: Annals of Oncology (2016)
Comparative Single Cell Analysis of Side Population (SP) / CD45+ Cells from Marrow and Skeletal Muscle Reveals Evidence of Genuine Stem Cell Function and Multilineage Differentiation Ability in Muscle-Resident Stem Cells.
Authors: Celine Haond, Francoise Farace, Martine Guillier, Yann Lecluse, Ludmilla Mecaj, Frederic Mazurier, William Vainchenker, Ali G. Turhan
Journal: Blood (2004)
Quality of Life, Risk Perception, and Treatment Burden with Peanut Oral Immunotherapy
Authors: Jennifer S. LeBovidge, Rima A. Rachid, Andrew MacGinnitie, William Secor, Elizabeth S. Burke-Roberts, Jacqueline A. Pongracic, Jonathan M. Spergel, Kari Nadeau, Dale T. Umetsu, Lynda C. Schneider
Journal: Journal of Allergy and Clinical Immunology (2017)
Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
Authors: O. Caffo, E. Biasco, G. Facchini, L. Fratino, D. Gasparro, C. Mosillo, U. Basso, D. Santini, M. Tucci, C. Ortega, F. Verderame, S. Scagliarini, G.L.o. Re, G. Procopio, G. Fornarini, E. Campadelli, R. Sabbatini, F. Maines, U. De Giorgi
Journal: Annals of Oncology (2016)
Distinct Methylation Patterns among Infants with MLL Rearranged Acute Lymphoblastic Leukemia.
Authors: Dominique J.P.M. Stumpel, Pauline Schneider, Eddy H.J. van Roon, Judith M. Boer, Renee X. Menezes, Rob Pieters, Ronald W. Stam
Journal: Blood (2007)
Evaluation of Indoor Microbiota in Wisconsin Farm Vs. Non-farm Homes Using Electrostatic Dust Collectors
Authors: Mariam Wahidi, Rose F. Vrtis, Kei E. Fujimura, Susan V. Lynch, D.J.J. Heederik, Matthew C. Keifer, Iris A. Reyes, Casper G. Bendixsen, Christine M. Seroogy, James E. Gern
Journal: Journal of Allergy and Clinical Immunology (2017)
ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors.
Authors: Essam Ahmed Ghazaly, Ivana Rizzuto, Hani Gabra, Nagy A Habib, Robert C. F. Leonard, Harpreet Wasan, Christopher McGuigan, Sarah Patricia Blagden
Journal: Journal of Clinical Oncology (2014)

2531 Background: Acelarin (NUC-1031) is a first-in-class nucleotide designed to overcome key cancer cell resistance by having nucleoside transporter-independent cellular uptake, activity independent of deoxycytidine kinase and being resistant to cytidine deaminase inactivation. Methods: The ProGem1 study objectives were to establish the MTD, PK, safety profile and clinical activity of Acelarin in patients with advanced, rapidly progressing treatment-resistant or refractory solid tumours. Acelarin was administered by 10 minute IV injection on a weekly (D1, 8 and 15 of a Q28 schedule), or twice weekly schedule, for 6 cycles. Acelarin doses ranged from 375 to 1000 mg/m2. Compassionate use was allowed after 6 cycles for those benefiting from treatment. Results: To date, 29 patients (pts), with a mean age of 57 yrs (range 35-73 yrs), have been enrolled with: ovarian (5), breast (3), colorectal (3), mesothelioma (3), CUP (3), uterine (3), pancreatic (3), cholangiocarcinoma (2), lung (2), and other (2) primary disease. 26 pts had metastatic disease. Pts had received a mean of 2.6 prior lines of therapy (range 1-7). DLTs were: G3 raised AST in 1/6 at 725mg/m2; G4 thrombocytopenia in 1/6 at 750mg/m2; G4 injection site pain in 1 at 1000mg/m2; and G4 thrombocytopenia in 1/6 at 375mg/m2 twice weekly. The most common (>20%) adverse events (AEs) were grade 1-2, and reversible: thrombocytopenia (22%), fatigue (22%), and hypoalbuminaemia (21%). High intracellular levels of the active anti-cancer agent dFdCTP were rapidly achieved and maintained for 24 hours, confirming Acelarin’s ability to bypass the key resistance pathways. Responses evaluated by RECIST were: 5 PR (17%); 13 SD (45%); with an ITT Disease Control Rate (DCR) of 62%; and, an OTA DCR of 90% in patients refractory or resistant to standard chemotherapy. All 6 pts who received ≥2 cycles of Acelarin, and were refractory / relapsed on prior gemcitabine, achieved disease control. Disease control in all patients has been durable (range 3 to >12 months; mean 5.8 months). Conclusions: Acelarin is a well tolerated, first-in-class nucleotide that has achieved a high, durable Disease Control Rate (ITT 62%; OTA 90%) in a wide range of advanced refractory / resistant cancers. Clinical trial information: NCT01621854.
Chemoradiotherapy versus surgery for clinical stage I esophageal squamous cell carcinoma: a long-term comparison
Authors: Seiichiro Mitani, Shigenori Kadowaki, Isao Oze, Hiroya Taniguchi, Takashi Ura, Masahiro Tajika, Chiyoko Makita, Takeshi Kodaira, Norihisa Uemura, Tetsuya Abe, Kei Muro
Journal: Annals of Oncology (2016)
Evaluation of CD4+ Cell Recovery in Vivo Using Single Photon Emission Tomography (SPECT) in Real Time Following CD34+ Cell Transplantation in Rhesus Macaques
Authors: Robert E. Donahue, Sharat Srinivasula, Naoya Uchida, Insook Kim, Gorka Duralde, Paula DeGrange, Marisa St. Claire, Richard C. Reba, Aylin C. Bonifacino, Allen E. Krouse, Mark E. Metzger, Chang H. Paik, H. Clifford Lane, John F. Tisdale, Michele Di Mascio
Journal: Blood (2014)
Association between variants on 8q24 and prostate cancer: A review and meta-analysis.
Authors: Sarah M. Troutman, Tristan M. Sissung, Cheryl D. Cropp, David J. Venzon, Shawn D. Spencer, Douglas K. Price, William Douglas Figg
Journal: Journal of Clinical Oncology (2012)

28 Background: Racial disparities in the incidence prostate cancer exist but remain unexplained. Recent studies implicate single nucleotide polymorphisms (SNPs) within the 8q24 region as a risk factor for prostate cancer (PCa) and the frequency of variant alleles at these SNPs appear to differ by race. To determine the association between 8q24 polymorphisms and PCa among men of different races, we performed meta-analyses, stratified by race. Methods: Twenty-nine studies of seven SNPs and one microsatellite marker located within the 8q24 region were included in the meta-analyses. Allelic odds ratio (OR) values and confidence intervals were calculated using the Mantel-Haenszel test. This test assumes homogeneity so we first used the Breslow-Day test to determine whether or not the assumption of homogeneity was valid in each population. Results: PCa risk was associated with the following SNPs in all included races: rs6983267, rs1447295, rs6983561, rs7837688, rs16901979, and DG8S737(-8). PCa risk in Caucasians was conferred by rs6983267 (OR = 1.22 (1.17-1.27)), rs1447295 (OR = 1.43 (1.45-1.49)), rs6983561 (OR = 1.45 (1.30-1.61), rs7837688 (OR = 1.55 (1.39-1.73)), rs16902979 (OR = 1.39 (1.29-1.49)), and DG8S737(-8) (OR = 1.32 (1.12-1.56)). In African American men, a significant association was found for rs1447295 (OR = 1.1 (1.02-1.18)), rs6983561 (OR = 1.43 (1.29-1.59)), rs16901979 (OR = 1.39 (1.29-1.49)), and DG8S737(-8) (OR =1.34 (1.19-1.50)). Alleles associated with PCa risk in Asians were rs6983267 (OR = 1.15 (1.04-1.26)), rs1447295 (OR = 1.39 (1.25-1.54)), rs6983561 (OR = 1.68 (1.51-1.88)), and rs16901979 (OR = 1.65 (1.48-1.85)). The risk allele at rs1447295 was also associated with PCa risk among Hispanic men. Conclusions: 8q24 contains SNPs that are associated with PCa risk, but the strength of this association depended on race. Racial disparities in the incidence of PCa may in part be accounted for by 8q24 variants.
Left Ventricular Global Function Index and Left Ventricular Mass Volume Ratio By CMR: Relation with Heart Failure in Thalassemia Major Patients
Authors: Antonella Meloni, Lucia De Franceschi, Domenico Maddaloni, Sabrina Carollo, Roberto Sarli, Carlo Cosmi, Giovan Battista Ruffo, Maria Giovanna Neri, Maria Chiara Resta, Antonino Vallone, Vincenzo Positano, Alessia Pepe
Journal: Blood (2014)
Long-Term Follow up of the Beneficial Effects and of Issues in Subtotal Splenectomy for Hereditary Spherocytosis
Authors: Thomas Pincez, Corinne Guitton, Frederic Gauthier, Guenolee Lambert, Veronique Picard, Madeleine feneant Thibault, Narla Mohandas, Gil Tchernia, Loic Garcon
Journal: Blood (2015)
PDCT-14. CHEMOTHERAPY BENEFITS SOME BUT NOT ALL HIGH GRADE GLIOMA PATIENTS
Authors: Yang Liu, Christine Pittman
Journal: Neuro-Oncology (2016)

Malignant glioma is frequently fatal. The current standard of care prolonged survival in phase III clinical trials. It is unclear though if these survival gains extend to the entire population of glioma patients. We retrospectively collected patients registered in a population-based database for primary high grade gliomas (HGGs, n = 363) treated in Rochester, NY from 2000 to 2014. We analyzed survival trends and evaluated treatment efficacies for these patients. To externally validate our local population, we also performed survival and medication analysis for glioblastoma (GBM) patients from The Cancer Genome Atlas (TCGA) database. The median age at diagnosis was 61 years. The majority of patients were white (94.5%) with GBM (77.7%). Most (84.3%) had died (all causes) during the follow-up interval. Overall, patients who received combination treatment of surgery, RT and chemotherapy have better survival (median 490.0 days) than those who received combination of surgery and RT (median 239.0 days, p<0.001) or surgery alone (median 95.0 days, p<0.001). We further grouped patients into three time periods for comparison: 2000 to 2004, 2005 to 2009, and 2010 to 2014. We found no appreciable differences in the median, 6-month, and 2-year survivals between each time interval (median survival time: 368.0 vs. 360.0 vs. 358.0 days, respectively) for all HGGs. Survival of GBM patients slightly increased, but this was exactly offset by worsening survival rates for grade III patients. While survival did not measurably change, our temozolomide administration increased significantly over the time (42.1% vs. 80.5% vs. 73.1%). Bevacizumab usage rose from 6.3% to 50.3% as well during the time. Similar flat survival trends in the face of increasing chemotherapy use were seen from the TCGA cohort. Our data indicate that chemotherapy, while effective, has benefits to a smaller group of patients than currently receive it.
Detection of Cells with Low Side Scatter and Dimmer CD45 Expression after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Good Survival
Authors: Yoshimitsu Shimomura, Hayato Maruoka, Yotaro Ochi, Yusuke Koba, Yuichiro Ono, Nobuhiro Hiramoto, Satoshi Yoshioka, Sumie Tabata, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Takayuki Ishikawa
Journal: Blood (2015)
Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.
Authors: Francois-Xavier Mahon, Delphine Rea, Francois Guilhot, Francoise Huguet, Franck Emmanuel Nicolini, Laurence Legros, Aude Charbonnier, Agnes Guerci, Bruno R. Varet, Gabriel Etienne, Emilie Aton, Josy Reiffers, Philippe Rousselot
Journal: Blood (2009)
Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study
Authors: G. Steger, E. Petru, F. Haslbauer, D. Egle, A. Galid, T. Sliwa, A. Lang, T. Kühr, A. Petzer, R. Ruckser, B. Mlineritsch, R. Greil, M. Seifert, C. Singer, J. Andel, W. Kwasny, C. Marth, P. Pichler, C. Tinchon, R. Bartsch
Journal: Annals of Oncology (2016)
CXCR4 Inhibitors Selectively Eliminate CXCR4 Expressing Human Acute Myeloid Leukemia Cells in NOG Mouse Model
Authors: Yanyan Zhang, Satyananda Patel, Monika Wittner, Stephane De Botton, Eric Solary, William Vainchenker, Paul Coppo, Fawzia Louache
Journal: Blood (2012)
Prolonged Half-Life and Improved Recovery of Recombinant Factor IX-XTEN Fusion Proteins in Hemophilia B Mouse Model
Authors: Arjan van der Flier, Zhiqian Lucy Liu, Zhan Liu, Oblaise Mercury, Ayman Ismail, Ekta Seth-Chhabra, John Kulman, Volker Schellenberger, David R. Light, Robert Peters
Journal: Blood (2015)
172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment
Authors: T. Ando, S. Yuki, H. Nakatsumi, T. Muranaka, A. Hosokawa, Y. Tsuji, M. Nakamura, O. Muto, T. Sasaki, I. Iwanaga, K. Hatanaka, A. Sato, None Eto, K. Furukawa, M. Tateyama, Y. Takahashi, T. Honda, Y. Sakata, Y. Komatsu
Journal: Annals of Oncology (2016)
NCOG-12. NEUROCOGNITION IN LOW-GRADE GLIOMAS: ASSOCIATIONS WITH MEASURABLE AND PERCEIVED IMPAIRMENTS
Authors: Katherine Peters, Mary Lou Affronti, Sarah Woodring, Janet Minchew, Eric Lipp, Frances McSherry, James Herndon, Dina Randazzo, Annick Desjardins, Gordana Vlahovic, Henry Friedman, Daniel Barboriak
Journal: Neuro-Oncology (2016)

After diagnosis, patients with low-grade gliomas (WHO grade II) can experience challenges that impact their health-related quality of life (HRQoL). One such impairment in HRQoL is neurocognitive dysfunction whether it is due to the underlying tumor or due to treatment including surgery, radiation, and chemotherapy. We sought to understand neurocognition in low-grade glioma patients and the associations with HRQoL including perceptions of their own neurocognition. In this study, 31 subjects with low-grade glioma underwent neurocognitive testing using a computerized program that assessed neurocognitive domains of cognitive flexibility, complex attention, executive functioning, psychomotor speed, processing speed, reaction time, verbal and visual memory. These measures and two HRQoL measures, the Functional Assessment of Cancer Therapy-Brain (FACT-Br) and Functional Assessment of Cancer Therapy-Cognition Function (FACT-Cog), were completed at baseline and 6 months later. Of the 31 subjects enrolled, majority were male (N=18, 58.1%), had ≥ 16 years of education (N=18, 58.1%), had KPS ≥90 (N=21, 67.7%), and had gross total resection (N=21, 67.7%). Only 4 subjects had prior radiation therapy, and 35.5% had prior chemotherapy. For all neurocognitive domains, there was no significant change in test scores over the 6 month period and a majority performed well with only 16.1-45.2% having standardized neurocognitive scores more than one standard deviation below the mean. Spearman’s rank correlation coefficients indicated perceived cognitive impairment, as measured by FACT-Cog, was significantly correlated with performance on domains of psychomotor speed (p=0.0049), complex attention (p=0.0059), cognitive flexibility (p=0.0133), and executive functioning (p=0.0279). Memory domains and reaction time did not correlate with perceived cognition on FACT-Cog. Less perceived cognitive impairment in low-grade glioma patients is associated with better performance on neurocognitive tests involving complex tasks such as complex attention and executive function. Identification of these particular impairments in low-grade glioma patients has the potential to improve HRQoL outcomes.